fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Dextroamphetamine sulfate

Form:

6 of 6 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Dexedrine · DIN 01924516 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Dexedrine · DIN 01924516 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-02-25 · brand DEXEDRINE · ATC N06BA02 DEXAMFETAMINE · form Tablet · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 5 MG · company Knight therapeutics inc. · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01924516)

Source record
DIN 01924516: Dexedrine Raw flags: sec3=Y Item: 282000003; group id 514; item number 1363; lccId None; manufacturer id KNT Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.8432; ministry $0.5081 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01924516 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15225
Interchangeable products
Dextroamphetamine · DIN 02443236 · $0.5081
Shortage status: resolved shortage (ended January 5, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924516
Shortage record checked October 6, 2026

Dextroamphetamine · DIN 02443236 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Dextroamphetamine · DIN 02443236 Manufacturer: A A Pharma Inc.; listing date 2016-03-30 Health Canada: Marketed since 2018-10-31 · brand DEXTROAMPHETAMINE · ATC N06BA02 DEXAMFETAMINE · form Tablet · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 5 MG · company Aa pharma inc · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Dextroamphetamine: Formulary list price $0.51 per unit (the source does not state the unit; exact figure $0.5081). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443236)

Source record
DIN 02443236: Dextroamphetamine Raw flags: sec3=Y Item: 282000003; group id 514; item number 1363; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.5081; ministry $0.5081 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443236 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92781
Interchangeable products
Dexedrine · DIN 01924516 · $0.5081
Shortage status: resolved shortage (ended September 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443236
Shortage record checked October 6, 2026

Dexedrine Spansules · DIN 01924559 · 10 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Dexedrine Spansules · DIN 01924559 Manufacturer: Paladin Pharma Inc.; listing date 2013-06-27 Health Canada: Marketed since 2026-02-25 · brand DEXEDRINE SPANSULE · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 10 MG · company Knight therapeutics inc. · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01924559)

Source record
DIN 01924559: Dexedrine Spansules Raw flags: sec3=Y Item: 282000010; group id 514; item number 1361; lccId None; manufacturer id PPI Source form: SR Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $1.2451; ministry $0.8096 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01924559 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15211 Therapeutic Notes (formulary) Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Teva-Dextroamphetamine SR · DIN 02448319 · $0.8096
Shortage status: anticipated shortage (last updated September 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924559
Shortage record checked October 6, 2026

Teva-Dextroamphetamine SR · DIN 02448319 · 10 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Teva-Dextroamphetamine SR · DIN 02448319 Manufacturer: Teva Canada Limited; listing date 2018-04-30 Health Canada: Marketed since 2025-08-13 · brand TEVA-DEXTROAMPHETAMINE SR · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 10 MG · company Teva canada limited · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Dextroamphetamine SR: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8096). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02448319)

Source record
DIN 02448319: Teva-Dextroamphetamine SR Raw flags: sec3=Y Item: 282000010; group id 514; item number 1361; lccId None; manufacturer id TEV Source form: SR Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.8096; ministry $0.8096 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02448319 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93401 Therapeutic Notes (formulary) Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Dexedrine Spansules · DIN 01924559 · $0.8096
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02448319
Shortage record checked October 6, 2026

Dexedrine Spansules · DIN 01924567 · 15 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Dexedrine Spansules · DIN 01924567 Manufacturer: Paladin Pharma Inc.; listing date 2013-06-27 Health Canada: Marketed since 2026-02-25 · brand DEXEDRINE SPANSULE · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 15 MG · company Knight therapeutics inc. · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01924567)

Source record
DIN 01924567: Dexedrine Spansules Raw flags: sec3=Y Item: 282000009; group id 514; item number 1362; lccId None; manufacturer id PPI Source form: SR Cap; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $1.5222; ministry $0.9898 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01924567 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15210 Therapeutic Notes (formulary) Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Teva-Dextroamphetamine SR · DIN 02448327 · $0.9898
Shortage status: resolved shortage (ended March 27, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924567
Shortage record checked October 6, 2026

Teva-Dextroamphetamine SR · DIN 02448327 · 15 mg · extended release capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Teva-Dextroamphetamine SR · DIN 02448327 Manufacturer: Teva Canada Limited; listing date 2018-04-30 Health Canada: Marketed since 2025-08-13 · brand TEVA-DEXTROAMPHETAMINE SR · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 15 MG · company Teva canada limited · schedule Controlled drugs (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Dextroamphetamine SR: Formulary list price $0.99 per unit (the source does not state the unit; exact figure $0.9898). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02448327)

Source record
DIN 02448327: Teva-Dextroamphetamine SR Raw flags: sec3=Y Item: 282000009; group id 514; item number 1362; lccId None; manufacturer id TEV Source form: SR Cap; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.9898; ministry $0.9898 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02448327 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93402 Therapeutic Notes (formulary) Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following: 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers. Administrative barriers include: - inability of a school to dose the child at lunch; - the school lunch hour does not coincide with the dosing schedule; - poor compliance with noon or afternoon doses; - the patient is unable to swallow tablets. Societal barriers include: - the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives; - the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Dexedrine Spansules · DIN 01924567 · $0.9898
Shortage status: active shortage (reported April 8, 2026, estimated to end October 30, 2026, last updated September 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02448327
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N06BA): coverage varies; not interchangeable

  • Lisdexamfetamine (Vyvanse): general benefit, not a benefit
  • Methylphenidate (Foquest): general benefit, not a benefit
  • Mixed salt amphetamine (Adderall XR): general benefit
  • Modafinil (Alertec): not a benefit
Other drugs in the same formulary class (28:20 C.N.S. Stimulants) and how they are covered

Matched class: 28:20 C.N.S. Stimulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE Some products covered without a code (check the product listing): LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE HCL 28:20 C.N.S. Stimulants

LISDEXAMFETAMINE DIMESYLATE

· 60 products · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg · Cap, Chew Tab

METHYLPHENIDATE HCL

· 47 products · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 25mg, 35mg, 45mg, 55mg, 70mg, 85mg, 100mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg, 18mg, 27mg, 36mg, 54mg · CR Cap, ER Cap, ER Tab, SR Tab, Tab

MIXED SALT AMPHETAMINE

· 24 products · General benefit · strengths: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg · ER Cap

MODAFINIL

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:20
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: an integral part of a total treatment program for adhd that may include other measures, attention deficit hyperactivity disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: MIXED SALT AMPHETAMINE GUANFACINE · Limited Use, codes 540 Indications Pediatrics (6 to 17 years of age) INTUNIV XR (guanfacine hydrochloride extended-release tablets) is indicated as: • monotherapy for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph Need for Comprehensive Treatment Program INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10 Product monograph MIXED SALT AMPHETAMINE · General benefit Indications ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: • Children (6 – 12 years of age) • Adolescents (13 – 17 years of age) • Adults (18 years of age or older) Need for Comprehensive Treatment Program ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10 Product monograph ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) Need for Comprehensive Treatment Program TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10 Product monograph LISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) Need for Comprehensive Treatment Program VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10 Product monograph METHYLPHENIDATE HCL · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) INDICATION AND CLINICAL USE pms-METHYLPHENIDATE is indicated for the treatment of:  Attention Deficit Hyperactivity Disorder (ADHD) Need for Comprehensive Treatment Program pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00068339.PDF; date October 17, 2022; DIN 00584991; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS DEXEDRINE/DEXEDRINE SPANSULE (dextroamphetamine sulfate) is indicated: • in the adjunctive treatment of narcolepsy • for the treatment of attention deficit hyperactivity disorder (ADHD) Attention Deficit Hyperactivity Disorder (ADHD): A diagnosis of ADHD (DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and that were present before age 7 years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive-Impulsive Type, at least 6… https://pdf.hres.ca/dpd_pm/00083629.PDF PM date: FEB 25, 2026 Source product: DEXEDRINE; DIN 01924516; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Dextroamphetamine SR · DIN 02448327 Shortage status: active shortage (reported 2026-04-08, estimated to end 2026-10-30, last updated 2026-09-25); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02448327

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18